Valuation: Zentalis Pharmaceuticals, Inc.

Market Cap 165M 147M 135M 123M 233M 15.44B 238M 1.62B 645M 8.27B 618M 605M 26.04B P/E 2026 *
-0.83x
P/E 2027 * -0.93x
Enterprise Value -39.82M -35.54M -32.71M -29.68M -56.26M -3.73B -57.65M -391M -156M -2B -149M -146M -6.29B EV / Sales 2026 *
-
EV / Sales 2027 * 4.29x
Free-Float
78.15%
Yield 2026 *
-
Yield 2027 * -
1 day+1.16%
1 week-5.95%
Current month-11.22%
1 month-34.09%
3 months-58.77%
6 months-60.54%
Current year+28.89%
1 week 1.63
Extreme 1.63
1.89
1 month 1.63
Extreme 1.63
2.64
Current year 1.32
Extreme 1.32
6.95
1 year 1.25
Extreme 1.25
6.95
3 years 1.01
Extreme 1.01
18.07
5 years 1.01
Extreme 1.01
85.95
10 years 1.01
Extreme 1.01
87.19
Manager TitleAgeSince
Chief Executive Officer 62 13/11/2024
Director of Finance/CFO - 13/11/2024
Chief Tech/Sci/R&D Officer 51 13/11/2024
Director TitleAgeSince
Chairman 61 16/05/2022
Director/Board Member 44 09/02/2021
Director/Board Member 59 12/09/2022
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 A Free

Chief Technology Officer

9,727 0.0103%
8/14/26 A Buy 4,335,000 4.5791%
5/26/26 A Free

Director

114,200 0.1604%
Change 5-day change 1-year change 3-year change Capi.($)
+1.16%-5.95%+35.94%-82.55% 163M
+2.24%+8.40%+58.47%+69.00% 66.7B
+4.66%+8.90%+16.93%+85.41% 56.88B
-0.60%+1.73%+24.32%+94.40% 56.53B
+2.55%+15.52%+30.43%+120.17% 46.49B
+2.58%+7.89%+32.49%+45.30% 44.8B
+4.09%+6.37%+228.06%+899.75% 41.59B
-0.47%+9.38%+27.53%+52.40% 35.35B
+3.80%-1.00%+98.16%+66.79% 33.29B
+1.48%+6.21%-38.80%+395.73% 25.1B
Average +2.15%+5.38%+51.35%+174.64% 41B
Weighted average by Cap. +2.29%+7.27%+53.74%+181.44%

Financials

2026 *2027 *
Net sales - 5.88M 5.25M 4.83M 4.39M 8.31M 551M 8.52M 57.81M 23.04M 295M 22.08M 21.61M 930M
Net income -162M -145M -133M -121M -229M -15.22B -235M -1.6B -636M -8.15B -609M -596M -25.66B -179M -160M -147M -133M -252M -16.75B -259M -1.76B -700M -8.97B -671M -656M -28.25B
Net Debt -205M -183M -168M -152M -289M -19.17B -296M -2.01B -801M -10.26B -768M -751M -32.33B -139M -124M -115M -104M -197M -13.07B -202M -1.37B -546M -7B -523M -512M -22.04B
Projected Income Statement - Annual - Zentalis Pharmaceuticals, Inc.
Logo Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is engaged in developing azenosertib (ZN-c3), a potentially first-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. The inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death and thereby preventing tumor growth and potentially causing tumor regression. WEE1 acts as a regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types.
Employees
106
Date Price Change Volume
09/11/26 $1.740 +1.16% 1,273,994
06/11/26 $1.720 +0.58% 1,294,443
05/11/26 $1.710 -2.84% 1,653,180
04/11/26 $1.760 -1.12% 1,115,991
03/11/26 $1.780 -3.78% 1,271,497
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Zentalis Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
1.740USD
Average target price
7.333USD
Spread / Average Target
+321.46%
  1. Stock Market
  2. Stocks
  3. ZNTL Stock